Logo_Biofrontera_AG.png
Biofrontera to Present at Two Upcoming Investor Conferences
12 juin 2019 10h58 HE | Biofrontera AG
Leverkusen, Germany, June 12, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Logo_Biofrontera_AG.png
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
16 mai 2019 04h30 HE | Biofrontera AG
Leverkusen, Germany, May 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo_Biofrontera_AG.png
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
16 avr. 2019 07h30 HE | Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Logo_Biofrontera_AG.png
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
25 mars 2019 10h00 HE | Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
Logo_Biofrontera_AG.png
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
20 mars 2019 10h50 HE | Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
Logo_Biofrontera_AG.png
Biofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year
25 févr. 2019 09h30 HE | Biofrontera AG
Leverkusen, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that...
Logo_Biofrontera_AG.png
Ruling by the U.S. District Court of Massachussetts
27 déc. 2018 15h31 HE | Biofrontera AG
Leverkusen, Germany, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today comments on a...
Logo_Biofrontera_AG.png
Biofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference
15 oct. 2018 04h19 HE | Biofrontera AG
Leverkusen, Germany, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann...
Logo_Biofrontera_AG.png
Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland
01 oct. 2018 09h08 HE | Biofrontera AG
Leverkusen, Germany, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the...
Logo_Biofrontera_AG.png
Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference
24 sept. 2018 07h44 HE | Biofrontera AG
Leverkusen, Germany, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas...